Shire : Recommends ADS Holders Reject TRC ...

July 29, 2016

Dublin, Ireland- July 29, 2016 - Shire plc (LSE: SHP) (NASDAQ: SHPG) has been notified of an unsolicited 'mini-tender' offer made by TRC Capital Corporation ('TRC Capital') to purchase up to 1,000,000 American Depositary Shares ('ADSs') of Shire, each representing three ordinary shares of Shire, at a price of $182.75 per ADS in cash. The offer is for approximately 0.33 percent of the outstanding ordinary shares of Shire.

Shire does not endorse this unsolicited mini-tender offer and recommends that ADS holders reject the offer and do not tender their ADSs in response to the offer. Shire is not associated with TRC Capital, its mini-tender offer or the mini-tender offer documentation.

ADS holders are cautioned that the mini-tender offer has been made at a price below market, representing a discount of 4.51% to the closing price of Shire ADSs on the NASDAQ Global Select Market on July 15, 2016, the last trading day before the mini-tender offer was commenced. In addition, the offer is highly conditional. TRC Capital's offer states that it may terminate the offer if, among other things, the market price of Shire ADSs declines since the close of business on July 15, 2016.

TRC Capital has made similar unsolicited mini-tender offers for shares of other public companies. Mini-tender offers are designed to seek less than 5% of a company's outstanding shares, thereby avoiding many disclosure and procedural requirements applicable to most bids under U.S. securities legislation.

The U.S. Securities and Exchange Commission (the 'SEC') has also published investor tips regarding mini-tender offers on its website at https://www.sec.gov/investor/pubs/minitend.htm. The SEC states: '[s]ome bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.' Shire also encourages brokers and dealers, as well as other market participants, to review the SEC's letter regarding broker-dealer mini-tender offer dissemination and disclosures on the SEC's website
at: http://www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

Shire urges investors to obtain current market quotations for their ADSs, consult with their broker or financial advisor and exercise caution with respect to TRC Capital's offer. According to TRC Capital's offer documents, Shire ADS holders who have already tendered their ADSs may withdraw their ADSs at any time before 12:01 a.m. (New York City time) on Tuesday, August 16, 2016 by following the procedures described in the TRC Capital offer documents.

Shire requests that a copy of this news release be included with all distributions of materials relating to TRC Capital's mini-tender offer.

FOR FURTHER INFORMATION PLEASE CONTACT:

NOTES TO EDITORS

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We have best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com